Trials / Completed
CompletedNCT01756612
A Study to Assess Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Participants Not in Dialysis Treated With Methoxy Polyethylene Glycol-Epoetin Beta (COMETE)
A Non-interventional Study to Assess the Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Patients Not in Dialysis Treated With Mircera®
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 551 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective, multicenter, observational study will evaluate the impact of comorbidity factors on the hemoglobin level in participants with chronic kidney disease who are not on dialysis and initiated on treatment with methoxy polyethylene glycol-epoetin beta (Mircera). Data will be collected for 9 months after initiation of methoxy polyethylene glycol-epoetin beta treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methoxy Polyethylene Glycol-Epoetin Beta | Methoxy polyethylene glycol-epoetin beta will be administered at the discretion of treating physician. Study protocol does not specify any treatment regimen. |
Timeline
- Start date
- 2012-11-21
- Primary completion
- 2015-03-25
- Completion
- 2015-03-25
- First posted
- 2012-12-27
- Last updated
- 2019-07-15
Locations
108 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01756612. Inclusion in this directory is not an endorsement.